The special immunotherapy edition of Perspective magazine is live

Blue Latitude Health|19th May 2016

As a creative marketing consultancy, we have a unique perspective on the challenges facing the broad range of stakeholders in the healthcare and pharma industry. As such, we've created this magazine to explore those challenges in depth from a variety of viewpoints.

In this supplementary issue, we’re taking a special look at immunotherapies, and more specifically, the growing buzz around “immuno-oncology” therapies. At the time of publication, Blue Latitude Health have worked with four of the eight immunotherapies currently approved by the FDA, so we’ve pooled our expertise across the different capabilities to give you a clear view on the fourth pillar of care in oncology.

 

The immunotherapy special issue covers:

  • Immunology in oncology as a therapy area – what it is, how it works, and where it’s heading from a medical and commercial point of view.
  • Key insights around positioning immuno-oncology products based on our hands-on experience working in this area.
  • What new immunotherapies in oncology mean for cancer patients and the doctors who would prescribe them, and in turn, what that means for pharma.
  • The immuno-therapy patient experience as a customer journey.

Maximising the commercial potential of the pharmaceutical pipeline

Blue Latitude Health|3rd April 2020

Decisions made early in the drug development process can define the limits of what’s possible for products and portfolios. So, why aren’t commercial teams always involved in these early conversations? In this Q&A we deep dive into early stage strategy, including how to break down these siloes and rethink drug development and clinical trial design.

read more

In-progress treatments for COVID-19: an attempt to simplify things

Manos Mastorakis|27th March 2020

Senior Associate Consultant, Manos Mastorakis, takes a look at a number of COVID-19 drugs that are already registered in clinical trials, providing analysis aiming to simplify the current landscape.

read more

Why I became a multiple myeloma patient advocate

Imogen Coupe|6th March 2020

BLH speaks to MM patient advocate, Peter McCleave, to find out how he has fought to remain positive throughout his treatment journey while simultaneously leading a successful campaign to get more people to sign up to be a blood stem cell donor.

read more